Zhejiang Taimei Medical Technology Co Ltd Class H (HK:2576)
:2576
Want to see HK:2576 full AI Analyst Report?
Top Page
Zhejiang Taimei Medical Technology Co Ltd Class H
(2576)
Select Model
Select Model
Rating:46Neutral
Price Target:
HK$4.50
▲(7.14% Upside)
Action:Reiterated
Date:04/27/26
The score is held back primarily by continued losses and persistently negative operating/free cash flow despite a notable 2025 operational rebound. Technical indicators also point to weak momentum, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Conservative balance sheet
Low leverage and a sizable equity base provide durable financial flexibility to fund operations and absorb losses while the business scales. This reduces short-term refinancing risk and supports continued investment in product and market development over the next several months.
Negative Factors
Persistent negative cash flow
Consistent negative operating and free cash flow forces reliance on external financing or equity, limiting organic reinvestment. Even with 2025 improvement, ongoing cash burn elevates execution and funding risk until operations become cash-positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a sizable equity base provide durable financial flexibility to fund operations and absorb losses while the business scales. This reduces short-term refinancing risk and supports continued investment in product and market development over the next several months.
Read all positive factors
Zhejiang Taimei Medical Technology Co Ltd Class H (2576) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.53B
Dividend YieldN/A
Average Volume (3M)61.29K
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees627
SectorHealthcare
Sector Strength45
IndustrySoftware - Application
Share Statistics
EPS (TTM)N/A
Shares Outstanding200,592,530
10 Day Avg. Volume68,100
30 Day Avg. Volume61,293
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)1.79
Price to Sales (P/S)4.02
P/FCF Ratio-46.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zhejiang Taimei Medical Technology Co Ltd Class H Business Overview & Revenue Model
Company Description
Zhejiang Taimei Medical Technology Co., Ltd. provides digital operation platform for the biopharma industry in China. The company offers TrialOS, a drug digital cooperation platform that connects the cycle of hospitals, pharmaceutical companies, t...
How the Company Makes Money
null...
Zhejiang Taimei Medical Technology Co Ltd Class H Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 132.05M | 499.28M | 551.16M | 573.14M | 549.22M | 466.18M |
| Gross Profit | 49.52M | 211.91M | 224.94M | 179.00M | 185.40M | 163.59M |
| EBITDA | -104.94M | -42.04M | -176.73M | -302.97M | -364.38M | -440.39M |
| Net Income | -116.28M | -41.74M | -214.61M | -346.78M | -412.91M | -479.61M |
Balance Sheet | ||||||
| Total Assets | 1.34B | 1.56B | 1.58B | 1.44B | 1.83B | 1.80B |
| Cash, Cash Equivalents and Short-Term Investments | 978.70M | 1.19B | 1.20B | 1.07B | 1.41B | 1.40B |
| Total Debt | 26.29M | 61.16M | 34.76M | 28.64M | 81.47M | 77.44M |
| Total Liabilities | 322.13M | 365.62M | 348.62M | 402.56M | 441.97M | 393.75M |
| Stockholders Equity | 942.04M | 1.12B | 1.16B | 978.33M | 1.31B | 1.41B |
Cash Flow | ||||||
| Free Cash Flow | -113.03M | -43.15M | -207.30M | -360.64M | -357.44M | -249.94M |
| Operating Cash Flow | -112.56M | -39.38M | -201.62M | -351.16M | -329.22M | -217.53M |
| Investing Cash Flow | 297.63M | 328.99M | -283.68M | 237.69M | -5.88M | -379.35M |
| Financing Cash Flow | -4.42M | 24.90M | 281.04M | -39.28M | 285.59M | -40.08M |
Zhejiang Taimei Medical Technology Co Ltd Class H Technical Analysis
Negative
4.20
Price Trends
4.66
Negative
4.55
Negative
4.49
Positive
Market Momentum
0.03
Negative
43.65
Neutral
43.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2576, the sentiment is Negative. The current price of 4.2 is below the 20-day moving average (MA) of 4.62, below the 50-day MA of 4.66, and below the 200-day MA of 4.49, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 43.65 is Neutral, neither overbought nor oversold. The STOCH value of 43.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2576.
Zhejiang Taimei Medical Technology Co Ltd Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$376.45M | 4.98 | 4.28% | 7.10% | -2.78% | -24.77% | |
64 Neutral | HK$553.90M | 5.13 | 16.21% | 4.94% | 16.46% | 50.51% | |
54 Neutral | HK$245.85M | 15.20 | 2.98% | 28.00% | 25.18% | 245.83% | |
52 Neutral | HK$303.64M | 4.11 | 3.54% | 3.75% | 9.74% | 32.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$2.53B | ― | -3.66% | ― | ― | ― | |
45 Neutral | HK$183.53M | -8.21 | -33.69% | ― | -28.56% | 0.58% |
* Healthcare Sector Average
HK:2576
Zhejiang Taimei Medical Technology Co Ltd Class H
4.49
1.14
34.03%
HK:1419
Human Health Holdings Ltd.
0.80
0.01
1.27%
HK:1612
Vincent Medical Holdings Limited
0.84
0.45
115.38%
HK:3390
Tycoon Group Holdings Limited
0.28
-0.18
-38.89%
HK:0557
China Tian Yuan Healthcare Group Limited
0.46
-0.34
-42.50%
HK:0722
UMP Healthcare Holdings Limited
0.47
0.08
20.20%
Zhejiang Taimei Medical Technology Co Ltd Class H Corporate Events
Zhejiang Taimei Narrows 2025 Loss as AI Clinical Platform Bookings Surge
Mar 30, 2026
Zhejiang Taimei Medical Technology reported audited results for 2025 showing it remains focused on AI-powered clinical development solutions, having supported over 10,000 clinical trials since inception. Its platform strategy centers on integratin...
Zhejiang Taimei Expands Investment Partnership With Government-Backed Fund
Mar 30, 2026
Zhejiang Taimei Medical Technology has amended the terms of an investment partnership to bring in Jiaxing Yangtze River Delta Angel Venture Capital Partnership as a new limited partner, raising the vehicle’s total committed capital from RMB2...
Zhejiang Taimei Schedules Board Meeting to Approve 2025 Results and Consider Dividend
Mar 16, 2026
Zhejiang Taimei Medical Technology Co., Ltd. has scheduled a board meeting for March 30, 2026, to review and approve the group’s annual results for the financial year ended December 31, 2025. The board will also consider whether to recommend...
Zhejiang Taimei Medical Technology Shareholders Approve All Resolutions at 2026 Extraordinary Meeting
Feb 15, 2026
Zhejiang Taimei Medical Technology Co., Ltd. announced that all resolutions proposed at its first extraordinary general meeting of 2026 were approved by shareholders through a poll. The meeting, held in Shanghai and chaired by executive director a...
Zhejiang Taimei Details Capital Structure and Strategy for New Clinical Research Partnership
Feb 15, 2026
Zhejiang Taimei Medical Technology has issued supplemental details on a previously announced partnership that will invest in early-stage clinical trial pipelines, setting the initial total capital contribution at RMB227.27 million. The fund size i...
Zhejiang Taimei Calls EGM to Approve New 2026 H Share Award Scheme
Jan 28, 2026
Zhejiang Taimei Medical Technology Co., Ltd. has convened an extraordinary general meeting for 14 February 2026 in Shanghai to seek shareholder approval for a new 2026 H Share Award Scheme, capped at 10% of the company’s issued H shares (exc...
Zhejiang Taimei Medical Technology Proposes 2026 H Share Award Scheme and Initial Grants
Jan 28, 2026
Zhejiang Taimei Medical Technology Co., Ltd. has announced that its board approved the proposed adoption of a 2026 H Share Award Scheme, which will be implemented in compliance with Chapter 17 of the Hong Kong Listing Rules and remains subject to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.